Expression of melanoma-antigen-A (MAGE-A) in disseminated tumor cells in regional lymph nodes of patients with operable non-small cell lung cancer

Lung Cancer

Volumn 67, Issue 3, 2010, Pages 290-295

  Dango, Sebastian ^a   Wang, Xiao Tao ^a   Gold, Monika ^a   Cucuruz, Beatrix ^a   Klein, Christoph A ^b   Passlick, Bernward ^a   Sienel, Wulf ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Adjuvant immunotherapy; Disseminated tumor cells (DTCs); Lymph node metastasis; Melanoma antigen (MAGE); Non small cell lung cancer (NSCLC); Quantitative RT PCR

Indexed keywords

CYTOKERATIN 19; MELANOMA ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPH NODE CELL; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOTHERAPY; KERATIN-19; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PATIENT SELECTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSCRIPTION, GENETIC;

EID: 75749087989     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.04.012     Document Type: Article

References (45)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
3. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
4. Roselli M., Mariotti S., Ferroni P., Laudisi A., Mineo D., Pompeo E., et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: long-term survival in a randomized study. Int J Cancer 119 (2006) 955-960
5. Pantel K., Brakenhoff R.H., and Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8 (2008) 329-340
6. Pantel K., Schlimok G., Braun S., Kutter D., Lindemann F., Schaller G., et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85 (1993) 1419-1424
7. Takahashi K., Shichijo S., Noguchi M., Hirohata M., and Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 55 (1995) 3478-3482
8. Tomita Y., Kimura M., Tanikawa T., Nishiyama T., Morishita H., Takeda M., et al. Immunohistochemical detection of intercellular adhesion molecule-1 (ICAM-1) and major histocompatibility complex class I antigens in seminoma. J Urol 149 (1993) 659-663
9. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80 (1999) 219-230
10. Salgaller M.L. The development of immunotherapies for non-small cell lung cancer. Expert Opin Biol Ther 2 (2002) 265-278
11. Van Der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., van den E.B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
12. Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., and Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61 (2001) 5544-5551
13. Ohman F.K., and Nordqvist K. The melanoma antigen genes-any clues to their functions in normal tissues?. Exp Cell Res 265 (2001) 185-194
14. Honda T., Tamura G., Waki T., Kawata S., Terashima M., Nishizuka S., et al. Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 90 (2004) 838-843
15. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.P., De Smet C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40 (1994) 360-369
16. Kocher T., Zheng M., Bolli M., Simon R., Forster T., Schultz-Thater E., et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 100 (2002) 702-705
17. Tian X.X., Rai D., Li J., Zou C., Bai Y., Wazer D., et al. BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res 65 (2005) 4747-4753
18. Melloni G., Ferreri A.J., Russo V., Gattinoni L., Arrigoni G., Ceresoli G.L., et al. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 12 (2004) 145-151
19. De Smet C., Lurquin C., Lethe B., Martelange V., and Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19 (1999) 7327-7335
20. De Smet C., Loriot A., and Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 24 (2004) 4781-4790
21. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
22. Mountain C.F., and Dresler C.M. Regional lymph node classification for lung cancer staging. Chest 111 (1997) 1718-1723
23. Ruud P., Fodstad O., and Hovig E. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. Int J Cancer 80 (1999) 119-125
24. Noguchi S., Aihara T., Motomura K., Inaji H., Imaoka S., and Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 148 (1996) 649-656
25. Soong R., Beyser K., Basten O., Kalbe A., Rueschoff J., and Tabiti K. Quantitative reverse transcription-polymerase chain reaction detection of cytokeratin 20 in noncolorectal lymph nodes. Clin Cancer Res 7 (2001) 3423-3429
26. Wang X.T., Sienel W., Eggeling S., Ludwig C., Stoelben E., Mueller J., et al. Detection of disseminated tumor cells in mediastinoscopic lymph node biopsies and lymphadenectomy specimens of patients with NSCLC by quantitative RT-PCR. Eur J Cardiothorac Surg 28 (2005) 26-32
27. Pimpec-Barthes F., Danel C., Lacave R., Ricci S., Bry X., Lancelin F., et al. Association of CK19 mRNA detection of occult cancer cells in mediastinal lymph nodes in non-small cell lung carcinoma and high risk of early recurrence. Eur J Cancer 41 (2005) 306-312
28. Lugo T.G., Braun S., Cote R.J., Pantel K., and Rusch V. Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 21 (2003) 2609-2615
29. Kwon S., Kang S.H., Ro J., Jeon C.H., Park J.W., and Lee E.S. The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma. Cancer 104 (2005) 251-256
30. Kufer P., Zippelius A., Lutterbuse R., Mecklenburg I., Enzmann T., Montag A., et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 62 (2002) 251-261
31. Mecklenburg I., Stratakis D.F., Huber R.M., Haussinger K., Morresi-Hauf A., Riethmuller G., et al. Detection of melanoma antigen-A expression in sputum and bronchial lavage fluid of patients with lung cancer. Chest 125 (2004) 164S-166S
32. Jheon S., Hyun D.S., Lee S.C., Yoon G.S., Jeon C.H., Park J.W., et al. Lung cancer detection by a RT-nested PCR using MAGE A1-6 common primers. Lung Cancer 43 (2004) 29-37
33. Passlick B., Izbicki J.R., Kubuschok B., Thetter O., and Pantel K. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg 61 (1996) 177-183
34. Kubuschok B., Passlick B., Izbicki J.R., Thetter O., and Pantel K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small cell lung cancer. J Clin Oncol 17 (1999) 19-24
35. Gray J.W. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 4 (2003) 4-6
36. Schmidt-Kittler O., Ragg T., Daskalakis A., Granzow M., Ahr A., Blankenstein T.J., et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100 (2003) 7737-7742
37. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12 (2006) 5615-5621
38. Park J.W., Kwon T.K., Kim I.H., Sohn S.S., Kim Y.S., Kim C.I., et al. A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods 266 (2002) 79-86
39. Scott W.J., Howington J., Feigenberg S., Movsas B., and Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (2007) 234S-242S
40. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (2008) 3552-3559
41. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
42. Strauss G.M., Herndon J.E., Maddaus M.A., Johnstone D.W., Johnson E.A., Harpole D.H., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26 (2008) 5043-5051
43. Kruit W.H., van Ojik H.H., Brichard V.G., Escudier B., Dorval T., Dreno B., et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117 (2005) 596-604
44. van Baren N., Bonnet M.C., Dreno B., Khammari A., Dorval T., Piperno-Neumann S., et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23 (2005) 1-14
45. Vansteenkiste J., Zielinski M., Linder A., Dahabre J., Esteban E., Malinowski W., et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (2007) 7554